Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Sonny who wrote (3721)	11/18/2000 12:16:45 PM
From: RJMC	Read Replies (2) \| Respond to of 5665

The latest MTSL Stock Letter changed Immunogen from a buy under $20 to a hold. Looks like they are finally reassessing where Immunogen should be. They had a brief discussion on the reports from the AACR meeting and talked about the secondary offering. There were two companies that MTSL placed as a hold. Immunogen and NPS Pharmaceuticals. NPS just finished with a secondary offering. Upon completion of the secondary offering the NPS stock went up over $7 a share! Don't doubt that Immunogen may do the same once the 4,000,000 shares and over allotments, if any, have been placed. MTSL is waiting for the dust to settle before they initiate new buy recommendations on NPS and Immunogen. Bob M. P.S. If any of you are interested in subscribing to the MTSL stock letter, just contact them at www.bioinvest.com.